Abstract
Traditional, non-steroidal anti-inflammatory agents (NSAIAs) are arachidonate metabolite related. Since arachidonate metabolites do not induce the whole range of inflammatory responses, their blockade does not produce anti-inflammatory actions as potent as those of the corticosteroids. The recent development of cytokine research reveals the wide range involvement of IL-1, IL-6 and tumour necrosis factor (TNF) in the inflammatory process. Therefore, cytokine antagonists produce the most effective means of treatment for inflammatory disorders and are as effective, or even more potent, than corticosteroids, without producing the side effects common to such compounds. The only IL-1 blocker available today is the natural IL-1 receptor antagonist (IL-1 RA), a polypeptide which is easily metabolised in the bloodstream with a very short half-life (21 minutes). Thus, active research has been carried out to develop stable, long-acting agents which can be taken by oral administration or by parenteral injections rath...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
